In summary, these findings demonstrate that hfCas13d‐mediated PLK1 suppression is capable of substantially attenuating the in vivo tumour growth of osteosarcoma xenografts, potentially through the regulation of Smad3 activity. This evidence concerns the gene SMAD3 and osteosarcoma.